Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Advaxis (ADXS) Share Price
News articles about Advaxis (NASDAQ:ADXS) have trended somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Advaxis earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 47.4345820855483 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Advaxis (NASDAQ:ADXS) opened at $2.96 on Friday. Advaxis has a 52 week low of $2.71 and a 52 week high of $10.06. The company has a market cap of $122.26, a PE ratio of -1.28 and a beta of 1.91.
Advaxis (NASDAQ:ADXS) last released its quarterly earnings results on Wednesday, December 20th. The biotechnology company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.02). Advaxis had a negative return on equity of 114.00% and a negative net margin of 776.63%. The firm had revenue of $1.76 million for the quarter, compared to analysts’ expectations of $3.05 million. analysts predict that Advaxis will post -2.36 EPS for the current year.
ADXS has been the subject of a number of recent analyst reports. ValuEngine cut shares of Advaxis from a “sell” rating to a “strong sell” rating in a research note on Tuesday, October 3rd. Cantor Fitzgerald set a $19.00 price target on shares of Advaxis and gave the stock a “buy” rating in a research note on Friday, December 22nd. Finally, HC Wainwright set a $23.00 price target on shares of Advaxis and gave the stock a “buy” rating in a research note on Wednesday, December 27th.
In other Advaxis news, CFO Sara Bonstein sold 12,734 shares of the business’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $3.19, for a total value of $40,621.46. Following the completion of the sale, the chief financial officer now directly owns 244,504 shares of the company’s stock, valued at approximately $779,967.76. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Robert Petit sold 12,625 shares of the business’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $3.19, for a total transaction of $40,273.75. Following the completion of the sale, the insider now directly owns 237,265 shares of the company’s stock, valued at $756,875.35. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 38,192 shares of company stock valued at $122,615. 7.21% of the stock is owned by corporate insiders.
Advaxis Company Profile
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.